HCV
Hepatitis C virus

Hepatitis C virus (HCV) is a positive-strand RNA virus grouped in the genus Hepacivirus within the family Flaviviridae. HCV is classified into at least 6 genotypes (gt), and its error-prone polymerase leads to more than 50 subtypes. The long open reading frame, which encodes the HCV polyprotein, is processed by host and viral proteases and gives rise to three structural proteins (the capsid protein core and envelope glycoproteins E1 and E2) and seven nonstructural (NS) proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B). NS2 and p7 are essential for virus assembly but not RNA replication, whereas NS3 to NS5B are involved in a membrane-associated RNA replicase complex (RC). The NS3 protein is composed of a serine protease and an RNA helicase/nucleoside triphosphatase (NTPase), NS4A serves as a cofactor for NS3 serine protease, NS5B is the RNA-dependent RNA polymerase, and NS5A is considered to play key roles in multiple steps of the HCV life cycle. NS5A inhibitors exhibit a rapid inhibition of virus infectivity shortly after administration to HCV-infected cells.

The HCV protein NS5A prevents the apoptosis-enabling loss of intracellular potassium by inhibiting Kv2.1 function and thus blocking hepatocyte cell death.

The HCV RNA-dependent RNA polymerase (RdRp) has long been a prime target for antiviral development because of its critical role in viral replication and the absence of a mammalian homologous enzyme.

The combination of lucidone and alpha interferon, the protease inhibitor Telaprevir, the NS5A inhibitor BMS-790052, or the NS5B polymerase inhibitor PSI-7977, synergistically suppresses HCV RNA replication.
### HCV Inhibitors & Agonists

<table>
<thead>
<tr>
<th>Compound</th>
<th>Cat. No.</th>
<th>Description</th>
</tr>
</thead>
</table>
| 2',5-Difluoro-2'-deoxycytidine | HY-129057 | Purity: >98%  
Clinical Data: 1 mg, 5 mg |

<table>
<thead>
<tr>
<th>Compound</th>
<th>Cat. No.</th>
<th>Description</th>
</tr>
</thead>
</table>
| ABT-072 | HY-101634 | Purity: >99.0%  
Clinical Data: Phase 2  
Size: 1 mg, 5 mg, 10 mg, 20 mg |

<table>
<thead>
<tr>
<th>Compound</th>
<th>Cat. No.</th>
<th>Description</th>
</tr>
</thead>
</table>
| AG-1478 (Tyrophostin AG-1478; NSC 693255) | HY-13524 | Purity: 99.74%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg |

<table>
<thead>
<tr>
<th>Compound</th>
<th>Cat. No.</th>
<th>Description</th>
</tr>
</thead>
</table>
| Anguizole | HY-13321 | Purity: 99.48%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg |

<table>
<thead>
<tr>
<th>Compound</th>
<th>Cat. No.</th>
<th>Description</th>
</tr>
</thead>
</table>
| Asunaprevir (BMS-650032) | HY-14434 | Purity: 99.74%  
Clinical Data: Launched  
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg |

<table>
<thead>
<tr>
<th>Compound</th>
<th>Cat. No.</th>
<th>Description</th>
</tr>
</thead>
</table>
| Azuudine (RO-0622; FNC) | HY-19314 | Purity: >98%  
Clinical Data: No Development Reported  
Size: 1 mg, 5 mg |
<table>
<thead>
<tr>
<th>Cat. No.</th>
<th>Name</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>HY-19314A</td>
<td>Azudine hydrochloride</td>
<td>(RO-0622 hydrochloride; FNC hydrochloride) Azudine (RO-0622) hydrochloride is a potent nucleoside reverse transcriptase inhibitor (NRTI), with antiviral activity on HIV, HBV and HCV. Purity: &gt;97.0% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>HY-10443A</td>
<td>Balapiravir hydrochloride</td>
<td>(Ro 4588161 hydrochloride; R1626 hydrochloride) Balapiravir hydrochloride (Ro 4588161; R1626) is an orally active prodrug of a nucleoside analogue inhibitor of the RNA-dependent RNA polymerase (RdRP) of HCV (R1479; 4′-Azidocytidine). Balapiravir hydrochloride has anti-HCV activity. Purity: &gt;98% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>HY-10237</td>
<td>Boceprevir</td>
<td>(EBP 520; SCH 503034) Boceprevir is a novel, potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with Kd of 14 nM in both enzyme assay and EC50 of 350 nM in cell-based replicon assay. Purity: 99.00% Clinical Data: Launched Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg</td>
</tr>
<tr>
<td>HY-16134A</td>
<td>Celgosivir hydrochloride</td>
<td>(MBI 3253 hydrochloride; MDL 28574; MX3253 hydrochloride) Celgosivir hydrochloride (MBI 3253; MDL 28574; MX3253) is an α-glucosidase I inhibitor; inhibits bovine viral diarrhoea virus (BVDV) with an IC50 of 1.27 μM in vitro assay. Purity: &gt;98% Clinical Data: Phase 2 Size: 1 mg, 5 mg</td>
</tr>
<tr>
<td>HY-30234A</td>
<td>Clemizole hydrochloride</td>
<td>Clemizole hydrochloride is an H1 histamine receptor antagonist, found to substantially inhibit HCV replication. The IC50 of Clemizole for RNA binding by NS4B is 24±1 nM, whereas its EC50 for viral replication is 8 μM. Purity: 99.32% Clinical Data: Launched Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>HY-112712</td>
<td>Cyclophilin inhibitor 1</td>
<td>Cyclophilin inhibitor 1 is a potent and orally bioavailable cyclophilin A inhibitor, with a Kd of 5 nM, shows effective anti-HCV activity, with an EC50 of 98 nM for HCV 2a. Purity: &gt;98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</td>
</tr>
</tbody>
</table>
Daclatasvir (BMS-790052, EBP 883)  Cat. No.: HY-10466
Daclatasvir is a potent HCV NS5A protein inhibitor, with mean EC_{50} values of 50 and 9 pM against genotype 1a and 1b replicons, respectively.

Purity: 99.24%
Clinical Data: Launched
Size: 10 mM \times 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Daclatasvir dihydrochloride (BMS-790052 dihydrochloride)  Cat. No.: HY-10465
Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is a highly selective inhibitor of HCV NS5A with EC_{50} of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype 2a infectious virus in cell culture.

Purity: 99.62%
Clinical Data: Launched
Size: 10 mM \times 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Daclatasvir Impurity B  Cat. No.: HY-133247
Daclatasvir Impurity B is the impurity of Daclatasvir. Daclatasvir is a potent HCV NS5A protein inhibitor.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Daclatasvir Impurity C  Cat. No.: HY-133248
Daclatasvir Impurity C is the impurity of Daclatasvir. Daclatasvir is a potent HCV NS5A protein inhibitor.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Danoprevir (ITMN-191; R7227; RO5190591; RG7227)  Cat. No.: HY-10238
Danoprevir (ITMN-191) is an orally active NS3/4A protease inhibitor for hepatitis C virus (HCV) with an IC_{50} of 0.29 nM and is selective for NS3/4A over a panel of 53 proteases (IC_{50} higher than 10 \mu M).

Purity: 98.04%
Clinical Data: Launched
Size: 10 mM \times 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

Dasabuvir (ABT-333)  Cat. No.: HY-13998
Dasabuvir (ABT-333) is a nonnucleoside inhibitor of the RNA-dependent RNA polymerase encoded by the HCV NS5B gene, inhibits recombinant NS5B polymerases derived from HCV genotype 1a and 1b clinical isolates, with IC_{50} between 2.2 and 10.7 nM.

Purity: 98.40%
Clinical Data: Launched
Size: 10 mM \times 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

DDX3-IN-1  Cat. No.: HY-121832
DDX3-IN-1 (Compound 16f) is a DEAD-box polypeptide 3 (DDX3) inhibitor with CC{50} of 50 and 36 \mu M for HIV and HCV, respectively. Antiviral activity.

Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM \times 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Deapioplatycodin D  Cat. No.: HY-N0588
Deapioplatycodin D is a triterpenoid saponin isolated from Platycodon grandiflorum, with anti-HCV activity.

Purity: >95.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Deferiprone  Cat. No.: HY-80568
Deferiprone is the only orally active iron-chelating drug to be used therapeutically in conditions of transfusional iron overload.

Purity: 99.15%
Clinical Data: Launched
Size: 10 mM \times 1 mL, 500 mg, 1 g, 5 g

Elbasvir (MK-8742)  Cat. No.: HY-15789
Elbasvir (MK-8742) is a hepatitis C virus nonstructural protein 5A (HCV NS5A) inhibitor with EC_{50} of 4, 3 and 3 nM against genotype 1a, 1b, and 2a, respectively.

Purity: 99.97%
Clinical Data: Launched
Size: 2 mg, 5 mg, 10 mg, 50 mg, 100 mg
FGI-106
Cat. No.: HY-124618

FGI-106 is a potent and broad-spectrum inhibitor with inhibitory activity against multiple viruses. FGI-106 is active against Ebola, Rift Valley and Dengue Fever viruses with EC50s of 100 nM, 800 nM and 400-900 nM, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FGI-106 tetrahydrochloride
Cat. No.: HY-124618A

FGI-106 tetrahydrochloride is a potent and broad-spectrum inhibitor with inhibitory activity against multiple viruses. FGI-106 tetrahydrochloride is active against Ebola, Rift Valley and Dengue Fever viruses with EC50s of 100 nM, 800 nM and 400-900 nM, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Filibuvir
Cat. No.: HY-10118

Filibuvir is a potent, selective non-nucleoside inhibitor (NNI) of the HCV nonstructural 5B protein (NS5B) RNA-dependent RNA polymerase, and it binds noncovalently in the “Thumb 2” pocket of NS5B.

Purity: >99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gentiopticroside (Gentiopicrin)
Cat. No.: HY-N0494

Gentiopticroside, a naturally occurring iridoid glycoside, inhibits P450 activity, with an IC50 and a K, of 61 μM and 22.8 μM for CYP2A6; Gentiopticroside has anti-inflammatory and antioxidative effects.

Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM x 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Glcaprevir (ABT-493)
Cat. No.: HY-17634

Glcaprevir is a novel HCV NS53/4A protease inhibitor, with IC50 values ranging from 3.5 to 11.3 nM.

Purity: 99.93%
Clinical Data: Launched
Size: 10 mM x 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

Grazoprevir (MK-5172)
Cat. No.: HY-15298

Grazoprevir (MK-5172) is a selective inhibitor of Hepatitis C virus NS3/4A protease with broad activity across genotypes and resistant variants, with Ks of 0.01 nM (gt1b), 0.01 nM (gt2a), 0.08 nM (gt2a), 0.15 nM (gt3a), respectively.

Purity: 99.21%
Clinical Data: Launched
Size: 10 mM x 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Grazoprevir hydrate (MK-5172 hydrate)
Cat. No.: HY-15298B

Grazoprevir hydrate (MK-5172 hydrate) is a selective inhibitor of Hepatitis C virus NS3/4A protease with broad activity across genotypes and resistant variants, with Ks of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively.

Purity: 99.10%
Clinical Data: Launched
Size: 10 mM x 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Grazoprevir potassium salt (MK-5172 potassium salt)
Cat. No.: HY-15298A

Grazoprevir potassium salt (MK-5172 potassium salt) is a selective inhibitor of Hepatitis C virus NS3/4A protease with broad activity across genotypes and resistant variants, with Ks of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively.

Purity: 99.35%
Clinical Data: Launched
Size: 10 mM x 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Grazoprevir sodium salt (MK-5172 sodium salt)
Cat. No.: HY-15298C

Grazoprevir sodium salt (MK-5172 sodium salt) is a selective inhibitor of Hepatitis C virus NS3/4A protease with broad activity across genotypes and resistant variants, with Ks of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively.

Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg
**GS-443902**

(GS-441524 triphosphate; Remdesivir metabolite)  
Cat. No.: HY-126303

GS-443902 (GS-441524 triphosphate) is a potent viral RNA-dependent RNA-polymerases (RdRp) inhibitor with IC\textsubscript{50} of 1.1 μM, 5 μM for RSV RdRp and HCV RdRp, respectively. GS-443902 is the active triphosphate metabolite of Remdesivir.

**Clinical Data:** No Development Reported  
**Size:** 5 mg, 10 mg, 25 mg

**Purity:** 99.87%

---

**GS-443902 trisodium**  
(GS-441524 triphosphate trisodium; Remdesivir metabolite trisodium)  
Cat. No.: HY-126303C

GS-443902 trisodium (GS-441524 triphosphate trisodium) is a potent viral RNA-dependent RNA-polymerases (RdRp) inhibitor with IC\textsubscript{50} of 1.1 μM, 5 μM for RSV RdRp and HCV RdRp, respectively. GS-443902 trisodium is the active triphosphate metabolite of Remdesivir (GS-5734).

**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg, 10 mg

**Purity:** 99.15%

---

**HCV-IN-29**  
Cat. No.: HY-136266

HCV-IN-29 is a hepatitis C virus (HCV) inhibitor exacted from patent US8329159B2, compound 1e.

**Purity:** >98%

---

**HCV-IN-3**  
Cat. No.: HY-18564

HCV-IN-3 is a hepatitis C virus (HCV) NS3/4a protein inhibitor, with an IC\textsubscript{50} of 20 μM, a K\textsubscript{i} of 29 μM.

**Purity:** >98%

---

**HCV-IN-4**  
Cat. No.: HY-P0162

HCV-IN-4 is a potent and orally active HCV NS5A inhibitor, shows great potency against GT1a, GT2b, GT3a, GT1a Y93H and GT1a L31V, with IC\textsubscript{50} of 3 pM, 0.3 nM, 0.01 nM, 0.5 nM and 0.02 nM, respectively.

**Purity:** >98%

---

**HCV-IN-7**  
Cat. No.: HY-133018

HCV-IN-7 is an orally active and potent pan-genotypic HCV NS5A inhibitor with IC\textsubscript{50} of 3-47 pM. HCV-IN-7 shows a superior pan-genotypic profile and a good pharmacokinetic profile coupled with a favorable liver uptake. HCV-IN-7 has anti-viral activity.

**Purity:** >98%

---

**HCV-IN-7 hydrochloride**  
Cat. No.: HY-133018A

HCV-IN-7 hydrochloride is an orally active and potent pan-genotypic HCV NS5A inhibitor with IC\textsubscript{50} of 3-47 pM. HCV-IN-7 hydrochloride shows a superior pan-genotypic profile and a good pharmacokinetic profile coupled with a favorable liver uptake.

**Purity:** >98%

---

**Honokiol**  
(NSC 293100)  
Cat. No.: HY-N0003

Honokiol is a bioactive, biphenolic phytochemical that possesses potent antioxidative, anti-inflammatory, antiangiogenic, and anticancer activities by targeting a variety of signaling molecules.

**Purity:** 99.90%

---

**IDX184**  
Cat. No.: HY-19558

IDX184 is a potent and orally bioavailable inhibitor of HCV replication. IDX184 potently inhibits HCV polymerase (IC\textsubscript{50}=0.31 μM, K\textsubscript{i}=52.3 nM).

**Purity:** >98%

---

**Cat. No.:**  
[0x0]

**Fax:** 609-228-5909

**Tel:** 609-228-6898

**Email:** sales@MedChemExpress.com
Inarigivir soproxil
(SB9200)
Cat. No.: HY-109035

Inarigivir soproxil is an agonist of innate immunity and shows potent antiviral activity against resistant hepatitis C virus (HCV) variants, with EC_{50} of 2.2 and 1.0 μM for HCV 1a/1b in cells of genotype 1 HCV replicon systems.

Purity: 98.16%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

JTK-853
Cat. No.: HY-19921

JTK-853 is a novel, non-nucleoside Hepatitis C Virus (HCV) polymerase inhibitor which shows effective antiviral activity in HCV replicon cells with EC_{50} of 0.38 and 0.035 μM in genotype 1a H77 and 1b Con1 strains, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KIN1408
Cat. No.: HY-19961

KIN1408 is an antiviral small molecule compound, as agonists of the RLR pathway.

Purity: 99.55%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Ledipasvir (acetone)
(GS-5885 acetone)
Cat. No.: HY-15602A

Ledipasvir acetone (GS-5885 acetone) is the active ingredient of Ledipasvir. Ledipasvir is an inhibitor of the hepatitis C virus NS5A, with EC_{50} values of 34 pM against GT1a and 4 pM against GT1b replicon.

Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ledipasvir D-tartrate
(GS-5885 D-tartrate)
Cat. No.: HY-15602B

Ledipasvir D-tartrate is an inhibitor of the hepatitis C virus NS5A, with EC_{50} values of 34 pM against GT1a and 4 pM against GT1b replicon.

Purity: 96.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ledipasvir
(GS-5885)
Cat. No.: HY-15602

Ledipasvir is an inhibitor of the hepatitis C virus NS5A, with EC_{50} of 34 pM against GT1a and 4 pM against genotype 1a and 1b replicon, respectively.

Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ledipasvir diacetone
(GS-5885 diacetone)
Cat. No.: HY-15602D

Ledipasvir diacetone (GS-5885 diacetone) is the active ingredient of Ledipasvir. Ledipasvir is an inhibitor of the hepatitis C virus NS5A, with EC_{50} values of 34 pM against GT1a and 4 pM against GT1b replicon.

Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

HY-109035

HY-B0376

Mecarbinate
(Dimecarbin; Dimecarbine; Dimekarbin)
Cat. No.: HY-B0376

Mecarbinate is an anti-hepatitis C virus (HCV) agent.

Purity: 98.34%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg
<table>
<thead>
<tr>
<th><strong>Cat. No.</strong></th>
<th><strong>Name</strong></th>
<th><strong>Description</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>HY-10240</td>
<td>Mericitabine</td>
<td>(RG 7128; R-7128; PSI 6130 disobutyrate) is a nucleoside inhibitor of the HCV NS5B polymerase that acts as an RNA chain terminator and prevents elongation of RNA transcripts during replication.</td>
</tr>
<tr>
<td>HY-125728</td>
<td>Micrococin P1</td>
<td>is a macrocyclic peptide antibiotic and is a potent hepatitis C virus (HCV) inhibitor with an EC&lt;sub&gt;50&lt;/sub&gt; range of 0.1-0.5 μM. Micrococin P1 has in vitro antibacterial activity against Gram-positive and Gram-negative bacterial strains. The MIC values of Micrococin P1 against S. aureus and E. coli are 0.24 μg/mL and 0.5 μg/mL, respectively.</td>
</tr>
<tr>
<td>HY-10244</td>
<td>MK-0608</td>
<td>is a potent and orally bioavailable inhibitor of HCV replication in vitro with an EC&lt;sub&gt;50&lt;/sub&gt; of 0.3 μM (EC&lt;sub&gt;90&lt;/sub&gt;≤ 1.3 μM) in the subgenomic-replicon assay.</td>
</tr>
<tr>
<td>HY-06620</td>
<td>Mulberroside C</td>
<td>is one of the main bioactive constituents in mulberry (Morus alba L.), and is a HCV replicon inhibitor. Antiviral activity.</td>
</tr>
<tr>
<td>HY-14775</td>
<td>Narlaprevir</td>
<td>(SCH 900518) is a potent, selective, orally bioavailable NS3 protease inhibitor (Ki=6 nM; EC50=40 nM).</td>
</tr>
<tr>
<td>HY-133246</td>
<td>Monodes(N-carboxymethyl)valine Daclatasvir</td>
<td>(Daclatasvir Impurity A) is the main degradation product of Daclatasvir. Daclatasvir is a potent HCV NS5A protein inhibitor.</td>
</tr>
<tr>
<td>HY-N6798</td>
<td>Myriocin</td>
<td>is a fungal metabolite isolated from Myriococcus albumyces, Isaria sinclairi and Mycelia sterilis, and is a potent inhibitor of serine-palmitoyl-transferase (SPT) and a key enzyme in de novo synthesis of sphingolipids.</td>
</tr>
<tr>
<td>HY-17470</td>
<td>Mizoribine</td>
<td>(NSC 289637; HE 69) is a potent inhibitor of inosine monophosphate dehydrogenase (IMPDH) with broad spectrum antiviral activities.</td>
</tr>
<tr>
<td>HY-13986</td>
<td>Merimepolid</td>
<td>(VX-497; MMPD) is a noncompetitive and oral inhibitor of inosine monophosphate dehydrogenase (IMPDH) with broad spectrum antiviral activities.</td>
</tr>
<tr>
<td>HY-10300</td>
<td>Nesbuvir</td>
<td>(HCV-796) is a nonnucleoside inhibitor of the hepatitis C virus (HCV) nonstructural protein 5B (NS5B) polymerase.</td>
</tr>
<tr>
<td>Compound</td>
<td>Cat. No.</td>
<td>Description and Details</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>---------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>NHC-triphosphate</td>
<td>HY-135867</td>
<td>NHC-triphosphate is an intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) as a triphosphate form. NHC-triphosphate is a weak alternative substrate for the viral polymerase and changes the mobility of the product in polyacrylamide electrophoresis gels. Purity: &gt;98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</td>
</tr>
<tr>
<td>NIM811</td>
<td>HY-P0025</td>
<td>NIM811 ((Melle-4)cyclosporin; SDZ NIM811) is an orally bioavailable mitochondrial permeability transition and cyclophilin dual inhibitor, which exhibits potent in vitro activity against hepatitis C virus (HCV). Purity: &gt;98% Clinical Data: Phase 2 Size: 10 mM × 1 mL, 1 mg, 5 mg</td>
</tr>
<tr>
<td>NM107</td>
<td>HY-10468</td>
<td>NM107 (2'-C-Methylcytidine; NM-107) is a nucleoside inhibitor of the hepatitis C virus (HCV) NS5B polymerase, the EC_{50} of NM107 in the wild-type replicon cells is 1.85 μM. Purity: 99.52% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>Nucleoside-Analog-1</td>
<td>HY-77651</td>
<td>Nucleoside-Analog-1 is a 4'-Azidocytidine analogue against Hepatitis C virus replication. Purity: &gt;95.0% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>Nucleoside-Analog-2</td>
<td>HY-77652</td>
<td>Nucleoside-Analog-2 is a 4'-Azidocytidine analogue against Hepatitis C virus (HCV) replication. Purity: &gt;95.0% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>Ombitasvir</td>
<td>HY-13997</td>
<td>Ombitasvir is a potent inhibitor of the hepatitis C virus protein NS5A, with EC_{50}s of 0.82 to 19.3 pM against HCV genotypes 1 to 5, and 366 pM against genotype 6a. Purity: 99.79% Clinical Data: Launched Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>Paritaprevir</td>
<td>HY-12594</td>
<td>Paritaprevir (ABT-450; Veruprevir) is a potent non-structural protein 3/4A (NS3/4A) protease inhibitor with EC_{50}s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Purity: 99.85% Clinical Data: Launched Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>Peretinoin</td>
<td>HY-100008</td>
<td>Peretinoin is an oral acyclic retinoid retinoid with a vitamin A-like structure that targets retinoid nuclear receptors such as retinoid X receptor (RXR) and retinoic acid receptor (RAR). Purity: 99.02% Clinical Data: Phase 3 Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>Platycodin D3</td>
<td>HY-N3519</td>
<td>Platycodin D3 is a triterpenoid saponin isolated from Platycodon grandiflorum, with anti-HCV activity. Purity: &gt;98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</td>
</tr>
</tbody>
</table>

www.MedChemExpress.com
<table>
<thead>
<tr>
<th>Product</th>
<th>Cat. No.</th>
<th>Description</th>
<th>Purity</th>
<th>Clinical Data</th>
<th>Size</th>
</tr>
</thead>
</table>
| **PSI-352938**  
(PSI-938) | HY-15231 | PSI-352938 (PSI-938) is a hepatitis C virus (HCV) nucleotide inhibitor. | > 98% | Phase 1 | 5 mg |
| **PSI-6130**  
(R 1656) | HY-10165 | PSI-6130 is a potent and selective inhibitor of HCV NS5B polymerase, and inhibits HCV replication with an IC<sub>50</sub> of 0.6 μM. | 99.39% | No Development Reported | 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg |
| **PSI-6206**  
(RO 2433; GS-331007) | HY-15236 | PSI-6206 (RO 2433) is the deaminated derivative of PSI-6130, which is a potent and selective inhibitor of HCV NS5B polymerase. PSI-6206 low potently inhibits HCV replicon with IC<sub>50</sub> of >100 μM. | 99.89% | No Development Reported | 10 mM × 1 mL, 1 mg, 5 mg, 10 mg |
| **PSI-6206 13CD3**  
(RO-2433 13CD3; GS-331007 13CD3; Sofosbuvir metabolite GS-331007 13CD3) | HY-15236S | PSI-6206 13CD3 is the deuterium labeled PSI-6206. PSI-6206 is the deaminated derivative of PSI-6130, which is a potent and selective inhibitor of HCV NS5B polymerase. PSI-6206 low potently inhibits HCV replicon with IC<sub>50</sub> of >100 μM. | >99.0% | No Development Reported | 10 mM × 1 mL, 1 mg, 5 mg, 10 mg |
| **PSI-7409** | HY-15745 | PSI-7409 is the active 5'-triphosphate metabolite of Sofosbuvir (PSI-7977). Sofosbuvir (PSI-7977) is a selective and highly active nucleotide analog inhibitor of HCV. | 96.49% | No Development Reported | 10 mM × 1 mL, 1 mg, 5 mg |
| **PSI-7409 tetrasodium** | HY-15745A | PSI-7409 tetrasodium is an active 5’-triphosphate metabolite of sofosbuvir (PSI-7977), inhibiting HCV NS5B polymerases, with IC<sub>50</sub> of 1.6, 2.8, 0.7 and 2.6 μM for GT 1b_Con1, GT 2a_JFH1, GT 3a, and GT 4a NS5B polymerases, respectively. | 96.49% | No Development Reported | 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg |
| **PSI-7976** | HY-15005A | PSI-7976 is the isomer of PSI-7977. PSI-7977 is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity. | 98.24% | No Development Reported | 10 mM × 1 mL, 1 mg, 5 mg |
| **R-1479**  
(4'-Azidocytidine) | HY-10444 | R-1479 (4’-Azidocytidine), a nucleoside analogue, is a specific inhibitor of RNA-dependent RNA polymerase (RdRp) of HCV. R-1479 inhibits HCV replication in the HCV subgenomic replicon system (IC<sub>50</sub>=1.28 μM). | 99.98% | No Development Reported | 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg |
| **Resiquimod**  
(R848; S28463) | HY-13740 | Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α. | 99.95% | Phase 2 | 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg |
| **Ribavirin**  
(ICN-1229) | HY-B0434 | Ribavirin (ICN-1229) is an antiviral agent against a broad spectrum of viruses including HCV, HIV, and RSV. | 99.80% | Launched | 10 mM × 1 mL, 100 mg, 200 mg, 500 mg |
### RIG-1 modulator 1

**Cat. No.: HY-107002**

RIG-1 modulator 1 is an anti-viral compound which can be useful for the treatment of viral infections including influenza virus, HBV, HCV and HIV extracted from patent WO 2015172099 A1.

<table>
<thead>
<tr>
<th>Purity</th>
<th>Clinical Data</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg</td>
</tr>
</tbody>
</table>

### RO8191 (RO4948191)

**Cat. No.: HY-W063968**

RO8191 (RO4948191), an imidazolophenanthridine compound, is an orally active and potent interferon (IFN) receptor agonist. RO8191 activate IFN-stimulated genes (ISGs) expression and JAK/STAT phosphorylation.

<table>
<thead>
<tr>
<th>Purity</th>
<th>Clinical Data</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg</td>
</tr>
</tbody>
</table>

### Sennidin A

Sennidin A, isolated from the leaves of Cassia angustifolia, inhibits HCV NS3 helicase, with an I_{50} of 0.8 μM. Sennidin A induces phosphorylation of Akt and glucose transporter 4 (GLUT4) translocation. Sennidin A stimulates the glucose incorporation.

<table>
<thead>
<tr>
<th>Purity</th>
<th>Clinical Data</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>5 mg, 10 mg</td>
</tr>
</tbody>
</table>

### Sennidin B

Sennidin B, a stereoisomer isolated from the leaves of Cassia angustifolia, has lower activity than Sennidin A. Sennidin A inhibits HCV NS3 helicase, with an I_{50} of 0.8 μM. Sennidin A induces phosphorylation of Akt and glucose transporter 4 (GLUT4) translocation.

<table>
<thead>
<tr>
<th>Purity</th>
<th>Clinical Data</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>5 mg, 10 mg</td>
</tr>
</tbody>
</table>

### Setrobuvir (ANA598)

**Cat. No.: HY-13247**

Setrobuvir (ANA598) is an orally active non-nucleosidic HCV NS5B polymerase inhibitor. ANA-598 inhibits both de novo RNA synthesis and primer extension, with IC_{50} between 4 and 5 nM. Setrobuvir also shows excellent binding affinity to SARS-CoV-2 RdRp and induces RdRp inhibition.

<table>
<thead>
<tr>
<th>Purity</th>
<th>Clinical Data</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg</td>
</tr>
</tbody>
</table>

### Simeprevir (TMC435)

**Cat. No.: HY-10241**

Simeprevir (TMC435) is an oral and potent HCV NS3/4A protease inhibitor with a K_{d} of 0.36 nM, and inhibits HCV replication with an EC_{50} of 7.8 nM.

<table>
<thead>
<tr>
<th>Purity</th>
<th>Clinical Data</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>99.46%</td>
<td>Launched</td>
<td>10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</td>
</tr>
</tbody>
</table>

### Sofosbuvir (PSI-7977; GS 7977)

**Cat. No.: HY-15005**

Sofosbuvir (PSI-7977) is an HCV RNA replication inhibitor with an EC_{50} of 92 nM.

<table>
<thead>
<tr>
<th>Purity</th>
<th>Clinical Data</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>99.99%</td>
<td>Launched</td>
<td>10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 500 mg, 1 g</td>
</tr>
</tbody>
</table>

### Sofosbuvir 13CD3 (PSI-7977 13CD3; GS-7977 13CD3)

**Cat. No.: HY-15005S**

Sofosbuvir 13CD3 is the deuterium labeled Sofosbuvir. Sofosbuvir (PSI-7977) is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.

<table>
<thead>
<tr>
<th>Purity</th>
<th>Clinical Data</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg</td>
</tr>
<tr>
<td>Product</td>
<td>Cat. No.</td>
<td>Purity</td>
</tr>
<tr>
<td>------------------</td>
<td>----------</td>
<td>----------</td>
</tr>
<tr>
<td>Sofosbuvir D6</td>
<td>HY-15005S1</td>
<td>98.35%</td>
</tr>
<tr>
<td>Sofosbuvir impurity A</td>
<td>HY-15005C</td>
<td>&gt;98%</td>
</tr>
<tr>
<td>Sofosbuvir impurity B</td>
<td>HY-I0719</td>
<td>&gt;98%</td>
</tr>
<tr>
<td>Sofosbuvir impurity D</td>
<td>HY-I0723</td>
<td>&gt;98%</td>
</tr>
<tr>
<td>Sofosbuvir impurity F</td>
<td>HY-I0406</td>
<td>97.62%</td>
</tr>
<tr>
<td>Sofosbuvir impurity G</td>
<td>HY-I0408</td>
<td>99.39%</td>
</tr>
<tr>
<td>Sofosbuvir impurity H</td>
<td>HY-I0938</td>
<td>&gt;98%</td>
</tr>
<tr>
<td>Sofosbuvir impurity I</td>
<td>HY-10512</td>
<td>97.70%</td>
</tr>
<tr>
<td><strong>Sofosbuvir impurity J</strong></td>
<td>Cat. No.: HY-10975</td>
<td></td>
</tr>
<tr>
<td>--------------------------</td>
<td>-------------------</td>
<td></td>
</tr>
<tr>
<td>Sofosbuvir impurity J, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.</td>
<td>Purity: &gt;98%  Clinical Data: No Development Reported  Size: 10 mM × 1 mL, 1 mg, 5 mg</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Sofosbuvir impurity K</strong></th>
<th>Cat. No.: HY-10515</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sofosbuvir impurity K, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.</td>
<td>Purity: 98.97%  Clinical Data: No Development Reported  Size: 10 mM × 1 mL, 1 mg, 5 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Sofosbuvir impurity L</strong></th>
<th>Cat. No.: HY-11196</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sofosbuvir impurity L, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.</td>
<td>Purity: &gt;98%  Clinical Data: No Development Reported  Size: 10 mM × 1 mL, 1 mg, 5 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Sofosbuvir impurity M</strong></th>
<th>Cat. No.: HY-10735</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sofosbuvir impurity M, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.</td>
<td>Purity: 99.04%  Clinical Data: No Development Reported  Size: 10 mM × 1 mL, 1 mg, 5 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Sofosbuvir impurity N</strong></th>
<th>Cat. No.: HY-10513</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sofosbuvir impurity N, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.</td>
<td>Purity: 98.66%  Clinical Data: No Development Reported  Size: 10 mM × 1 mL, 1 mg, 5 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Taribavirin</strong></th>
<th>Cat. No.: HY-10545</th>
</tr>
</thead>
<tbody>
<tr>
<td>Taribavirin is an orally active inosine monophosphate dehydrogenase inhibitor, has activity against a wide range of viruses, especially the hepatitis C virus and influenza virus.</td>
<td>Purity: &gt;98%  Clinical Data: No Development Reported  Size: 1 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Taribavirin hydrochloride</strong></th>
<th>Cat. No.: HY-10545A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Taribavirin hydrochloride is an orally active inosine monophosphate dehydrogenase inhibitor, has activity against a wide range of viruses, especially the hepatitis C virus and influenza virus.</td>
<td>Purity: 98.21%  Clinical Data: No Development Reported  Size: 1 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Telaprevir (VX-950)</strong></th>
<th>Cat. No.: HY-10235</th>
</tr>
</thead>
<tbody>
<tr>
<td>Telaprevir is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (K) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide.</td>
<td>Purity: 99.65%  Clinical Data: Launched  Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>TMC647055 Choline salt</strong></th>
<th>Cat. No.: HY-15591A</th>
</tr>
</thead>
<tbody>
<tr>
<td>TMC647055 choline salt is a cell-permeating, selective HCV NS5B inhibitor, eliciting a mean IC50 of 34 nM, as assessed in the RdRp primer-dependent transcription assay.</td>
<td>Purity: 99.75%  Clinical Data: Phase 2  Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
</tbody>
</table>
| **Tris(4-aminophenyl)methane**  
* (Leucopararosaniline) | **Vesatolimod**  
* (GS-9620) |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cat. No.: HY-D0306</td>
<td>Cat. No.: HY-15601</td>
</tr>
<tr>
<td>Tris(4-aminophenyl)methane is a triphenylmethane dye. Tris(4-aminophenyl)methane is a weak HCV helicase inhibitor.</td>
<td>Vesatolimod (GS-9620) is a potent, selective and orally active agonist of Toll-Like Receptor (TLR7) with an EC₅₀ of 291 nM.</td>
</tr>
</tbody>
</table>
| Purity: >98.0%  
Clinical Data: No Development Reported | Purity: 99.56%  
Clinical Data: Phase 2 |
| Size: 100 mg, 250 mg, 500 mg | Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg |

| **VCH-916** | **Velpatasvir**  
* (GS-5816) |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cat. No.: HY-13465</td>
<td>Cat. No.: HY-12530</td>
</tr>
<tr>
<td>VCH-916 is a novel nonnucleoside HCV NS5B polymerase inhibitor. IC₅₀ Value: Target: HCV VCH-916 is a novel allosteric inhibitor of HCV NS5B polymerase.</td>
<td>Velpatasvir (VEL, GS-5816) is a novel, potent and selective nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Target: NS5A.</td>
</tr>
</tbody>
</table>
| Purity: 99.51%  
Clinical Data: Phase 1 | Purity: 99.95%  
Clinical Data: Launched |
| Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg | Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg |

| **TTP-8307** | **VX-222**  
* (VCH-222) |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cat. No.: HY-124806</td>
<td>Cat. No.: HY-75800</td>
</tr>
<tr>
<td>TTP-8307 is a potent inhibitor of the replication of several rhino- and enteroviruses. TTP-8307 inhibits coxsackievirus B3 (CVB3; EC₅₀=1.2 μM) and poliovirus by interfering with the synthesis of viral RNA. TTP-8307 exerts antiviral activity through oxysterol-binding protein (OSBP).</td>
<td>VX-222 (VCH-222) is a novel, potent and selective inhibitor of HCV polymerase with IC₅₀ of 0.94-1.2 μM. 15.3-fold less effective for mutant M423T, and 108-fold less effective for mutant I482L.</td>
</tr>
</tbody>
</table>
| Purity: >98%  
Clinical Data: No Development Reported | Purity: 99.90%  
Clinical Data: Phase 2 |
| Size: 1 mg, 5 mg | Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg |